Abstract:Purpose/Objective: To evaluate dynamic contrast enhanced (DCE) MR parameters and correlate them with clinical prognostic factors, stage, nodal status and histology, for the early prediction of radiation therapy outcome in cervical cancer.Materials/Methods: Sixty-two cervical cancer patients stages IB2-IV treated with radiation/chemotherapy (RT/CT) underwent serial DCE MRI before (1st MRI), early (2nd MRI at 20–25 Gy/2 weeks) and at midpoint (3rd MRI at 40–50 Gy) of RT. Median follow up was 3.5 (0.9–6.3) years. MR parameters derived from the DCE curve, pixel histogram analysis of plateau signal intensity (SI) and lowest percentiles of poor-DCE tumor pixel populations within the entire tumor region, were correlated with local control and disease-free survival. The DCE parameters′ value as independent predictors was assessed by comparison with stage, histology and nodal status, using multivariate analysis.Results: DCE MR parameters predicted, as early as 2 weeks after RT start, local tumor control and disease-free survival (Figure). MR-based residual tumor volume and lowest 10th percentile of SI (SI 10) at 2 weeks were superior independent outcome predictors compared to stage, nodal status and histology (Table). The addition of the DCE MR parameters to clinical prognostic factors increased the sensitivity and specificity of the clinical factors from 71% and 62% to 100% and 76% for local recurrence, and from 83% and 68% to 100% and 82% disease-free survival. In low-risk patients (stage I–II, negative lymph nodes, n=33), SI 10<1.73 predicted local failure and death of disease with a sensitivity of 100% and specificity of 77%.Conclusions: This data suggests that microcirculation-based DCE MR parameters independently predict treatment outcome as early as 2 weeks after RT/CT start - allowing early modification of treatment to improve outcome. The predictive value of gold-standard clinical prognostic factors can be further enhanced by the addition of DCE-MR parameters.Tabled 1MR Parameters as Independent Predictors for Local Control and Disease-Free SurvivalKaplan-Meier analysis of disease-free survival based on lowest 10th SI percentile (≤1.73 vs. >1.73)View Large Image Figure ViewerDownload (PPT) Purpose/Objective: To evaluate dynamic contrast enhanced (DCE) MR parameters and correlate them with clinical prognostic factors, stage, nodal status and histology, for the early prediction of radiation therapy outcome in cervical cancer. Materials/Methods: Sixty-two cervical cancer patients stages IB2-IV treated with radiation/chemotherapy (RT/CT) underwent serial DCE MRI before (1st MRI), early (2nd MRI at 20–25 Gy/2 weeks) and at midpoint (3rd MRI at 40–50 Gy) of RT. Median follow up was 3.5 (0.9–6.3) years. MR parameters derived from the DCE curve, pixel histogram analysis of plateau signal intensity (SI) and lowest percentiles of poor-DCE tumor pixel populations within the entire tumor region, were correlated with local control and disease-free survival. The DCE parameters′ value as independent predictors was assessed by comparison with stage, histology and nodal status, using multivariate analysis. Results: DCE MR parameters predicted, as early as 2 weeks after RT start, local tumor control and disease-free survival (Figure). MR-based residual tumor volume and lowest 10th percentile of SI (SI 10) at 2 weeks were superior independent outcome predictors compared to stage, nodal status and histology (Table). The addition of the DCE MR parameters to clinical prognostic factors increased the sensitivity and specificity of the clinical factors from 71% and 62% to 100% and 76% for local recurrence, and from 83% and 68% to 100% and 82% disease-free survival. In low-risk patients (stage I–II, negative lymph nodes, n=33), SI 10<1.73 predicted local failure and death of disease with a sensitivity of 100% and specificity of 77%. Conclusions: This data suggests that microcirculation-based DCE MR parameters independently predict treatment outcome as early as 2 weeks after RT/CT start - allowing early modification of treatment to improve outcome. The predictive value of gold-standard clinical prognostic factors can be further enhanced by the addition of DCE-MR parameters.

MR-Predictive Assay in Preoperative Lung Cancer Therapy

Machine learning for prediction of chemoradiation therapy response in rectal cancer using pre-treatment and mid-radiation multi-parametric MRI

Dynamic Contrast-Enhanced Mri: Use in Predicting Pathological Complete Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer

Breast Cancer: Early Prediction of Response to Neoadjuvant Chemotherapy Using Parametric Response Maps for MR Imaging

Neoadjuvant Chemotherapy in Breast Cancer: Prediction of Pathologic Response with PET/CT and Dynamic Contrast-enhanced MR Imaging—Prospective Assessment

Enhancing Prediction for Tumor Pathologic Response to Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Cancer by Dynamic Parameters from Clinical Assessments

Dynamic Contrast-enhanced Area-detector CT vs Dynamic Contrast-enhanced Perfusion MRI vs FDG-PET/CT: Comparison of Utility for Quantitative Therapeutic Outcome Prediction for NSCLC Patients Undergoing Chemoradiotherapy

Early Assessment of Response to Chemotherapy in Lung Cancer Using Dynamic Contrast-Enhanced MRI: a Proof-of-concept Study

DCE-MRI Perfusion and Permeability Parameters as predictors of tumor response to CCRT in Patients with locally advanced NSCLC

Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching ‘liquid biopsy’ and quantitative tumor modeling

Prediction of pathological response grading for esophageal squamous carcinoma after neoadjuvant chemoradiotherapy based on MRI imaging using PDX

Evaluating the response of neoadjuvant chemotherapy for treatment of breast cancer: are tumor biomarkers and dynamic contrast enhanced MR images useful predictive tools?

Early Prediction of Treatment Outcome: Functional MR Imaging and Standard Clinical Prognostic Factors in Advanced Cervical Cancer

Usefulness of Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Predicting Treatment Response to Vinorelbine-Cisplatin with or Without Recombinant Human Endostatin in Bone Metastasis of Non-Small Cell Lung Cancer

Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI

Preoperative Evaluation of Pathologic Response in Patients with Breast Cancer by Dynamic Contrast-enhanced Magnetic Resonance Imaging

[Role of Magnetic Resonance Imaging for Response Evaluation and Predictive Value of Tumor Biomarkers in the Neoadjuvant Chemotherapy for Breast Cancer:A Multi-Center Prospective Study].

Predicting treatment response for the safe non-operative management of patients with rectal cancer using an MRI-based deep-learning model.

Prospective dynamic sampling and molecular residual disease monitoring to predict clinical outcomes for patients with unresectable, locally advanced non-small cell lung cancer undergoing radical radiotherapy.

Abstract P1-05-15: DCE-MRI for early prediction of excellent response versus chemoresistance in triple negative breast cancer

The Role of Dynamic Contrast-enhanced MRI for Evaluating Therapeutic Effect for NSCLC Patients with Chemotherapy or Chemoradiotherapy